First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists-Reference-Cited by-同舟云学术

First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Published:2022-10 Issue:10 Volume:175 Page:1392-1400
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Choi Jin G.¹^ORCID,Winn Aaron N.²,Skandari M. Reza³^ORCID,Franco Melissa I.¹^ORCID,Staab Erin M.¹,Alexander Jason¹^ORCID,Wan Wen⁴,Zhu Mengqi¹^ORCID,Huang Elbert S.⁴^ORCID,Philipson Louis⁵^ORCID,Laiteerapong Neda⁴^ORCID

Affiliation:

1. Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois (J.G.C., M.I.F., E.M.S., J.A., M.Z.)

2. Medical College of Wisconsin, Milwaukee, Wisconsin (A.N.W.)

3. Centre for Health Economics & Policy Innovation, Imperial College Business School, Imperial College London, London, United Kingdom (M.R.S.)

4. Section of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, Illinois (W.W., E.S.H., N.L.)

5. Sections of Adult and Pediatric Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Chicago, Chicago, Illinois (L.P.).

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

American Diabetes Association

National Institute on Aging

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Reference56 articles.

1. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

2. Economic Costs of Diabetes in the U.S. in 2017